aspirin + indobufen mimetic

This drug is a combination mimetic of aspirin and indobufen, both of which are antiplatelet agents used to prevent blood clot formation. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A2 production and thus platelet aggregation. Indobufen reversibly inhibits COX-1 with less impact on prostacyclin production, also inhibiting platelet aggregation by reducing thromboxane synthesis and platelet adhesion. The combination or mimetic aims to replicate the antiplatelet effects of both drugs, potentially offering efficacy comparable to aspirin with improved gastrointestinal safety similar to indobufen. Indobufen is considered an alternative for patients intolerant to aspirin due to fewer gastrointestinal side effects and lower bleeding risk while maintaining similar cardiovascular protective effects. Both drugs are primarily indicated for prevention of cardiovascular events such as myocardial infarction and stroke, especially in patients undergoing percutaneous coronary intervention (PCI). Clinical studies show that indobufen plus clopidogrel dual antiplatelet therapy (DAPT) is non-inferior in efficacy and safety compared to aspirin plus clopidogrel DAPT[1][2][3][4][5].